Percutaneous aortic valve replacement

Percutaneous aortic valve replacement
Intervention
ICD-9-CM 35.05

Percutaneous aortic valve replacement (PAVR), also known as transcatheter aortic valve implantation (TAVI) or transcatheter aortic valve replacement (TAVR), is the replacement of the aortic valve of the heart through the blood vessels (as opposed to valve replacement by open heart surgery). The replacement valve is delivered via one of several access methods: transfemoral (in the upper leg), transapical (through the wall of the heart), subclavian (beneath the collar bone), direct aortic (through a minimally invasive surgical incision into the aorta), and transcaval (from a temporary hole in the aorta near the belly button through a vein in the upper leg).

Severe symptomatic aortic stenosis carries a poor prognosis. Until recently, surgical aortic valve replacement has been the standard of care in adults with severe symptomatic aortic stenosis. However, the risks associated with surgical aortic valve replacement are increased in elderly patients and those with concomitant severe systolic heart failure or coronary artery disease, as well as in people with comorbidities such as cerebrovascular and peripheral arterial disease, chronic kidney disease, and chronic respiratory dysfunction.

Medical uses

Transcatheter aortic-valve replacement (TAVR) using a self-expanding transcatheter aortic-valve bioprosthesis (CoreValve) was associated with a significantly higher survival rate at 1 year follow-up than surgical aortic-valve replacement in a recent randomized study of 795 patients with severe aortic stenosis who were at increased surgical risk.[1][2]

A randomized, controlled study to test the safety and effectiveness of transcatheter heart valves in people with severe aortic stenosis; it published in 2011 and showed that the procedure was as safe and effective as open-heart surgery, and in those unable to receive surgery, it drastically improved survival[3] While there was high mortality (24.3% at 1 year and 33.9% at 2 years), it changed the standard of care for these people.[4]

History

The catheter procedure was developed in France, initially performed in 2002 on April 16 by Prof Alain Cribier in Hopital Charles Nicolle, at the University of Rouen.[5] It is now approved in more than 50 countries. It is effective in improving functioning in the patients with severe aortic stenosis. In the US, it received FDA approval in November 2011 for use in inoperable patients and in October 2012 for use in patients at high surgical risk.[6]

Devices

Medtronic’s CoreValve Transcatheter Aortic Valve is constructed of a self-expanding Nitinol frame and delivered through the femoral artery. This device received FDA approval in January 2014.[7][8][9]

Boston Scientific's Lotus Valve system was awarded CE approval in October 2013. It allows the final position to be assessed and evaluated before release and has been designed to minimise regurgitation.[9]

St Jude Medical's Portico Transcatheter aortic valve received European CE mark approval in December 2013. The valve is repositionable before release to ensure accurate placement helping to improve patient outcomes.[9]

Edwards' Sapien aortic valve is made from bovine pericardial tissue and is implanted via a catheter-based delivery system. It is approved by the FDA for use in the US.[7][8][9]

Implantation

The devices are implanted without open heart surgery. The valve delivery system is inserted in the body, the valve positioned and then implanted inside the diseased aortic valve, and then the delivery system is removed. The catheter based delivery system can be inserted into the body from one of several sites.

The transfemoral approach requires the catheter and valve to be inserted via the femoral artery. Similar to coronary artery stenting procedures, this is accessed via a small incision in the groin, through which the delivery system is slowly fed along the artery to the correct position at the aortic valve.

The transapical approach sees the catheter and valve inserted through the tip of the heart and into the left ventricle. Under general anesthesia, a small surgical incision is made between the ribs, followed by a small puncture of the heart. The delivery system is then fed slowly to the correct position at the aortic valve. The puncture in the heart is then sutured shut.

The transaortic approach sees the catheter and valve inserted through the top of the right chest. Under general anesthesia, a small surgical incision is made alongside the right upper breastbone, followed by a small puncture of the aorta. The delivery system is then fed slowly to the correct position at the aortic valve. The hole in the aorta is then sutured shut.

The transcaval approach has been applied to a smaller number of patients who are not eligible for transfemoral, transapical, or transaortic approaches. In the transcaval approach a tube is inserted via the femoral vein instead of the femoral artery, and a small wire is used to cross from the inferior vena cava into the adjacent abdominal aorta. Once the wire is across, a large tube is used to place the transcatheter heart valve through the femoral vein and inferior vena cava into the aorta and from there the heart. This otherwise resembles the transfemoral approach. Afterwards the hole in the aorta is closed with a self-collapsing nitinol device designed to close holes in the heart. [10][11]

References

  1. ↑ "Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis". New England Journal of Medicine 370: 1790–1798. May 8, 2014. doi:10.1056/NEJMoa1400590.
  2. ↑ "CoreValve Beats High-Risk Surgery for AV Stenosis in Pivotal Trial". March 29, 2014.
  3. ↑ Smith CR, Leon MB, Mack MJ, et al. (2011). "Transcatheter vs surgical aortic-valve replacement in high risk patients". N Engl J Med 364: 2187–98. doi:10.1056/NEJMoa1103510. PMID 21639811.
  4. ↑ Tomey MI, et al. (Nov 2013). "Cardiac critical care after transcatheter aortic valve replacement". Cardiol Clin. 31 (4): 607–18. doi:10.1016/j.ccl.2013.07.006. PMID 24188224.
  5. ↑ Cribier, A; Eltchaninoff H; Bash A; Borenstein N; Tron C; Bauer F; Derumeaux G; Anselme F; Laborde F; Leon MB (10 December 2002). "Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis. First human case description.". Circulation 106 (24): 3006–3008. doi:10.1161/01.cir.0000047200.36165.b8. PMID 12473543.
  6. ↑ http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm278348.htm
  7. 1 2 Medscape. "Transcatheter Aortic Valve Replacement Devices". Retrieved December 2013.
  8. 1 2 Agarwal S, et al. (Feb 2015). "Transcatheter aortic valve replacement: current perspectives and future implications". Heart 101 (3): 169–77. doi:10.1136/heartjnl-2014-306254. PMID 25410500.
  9. 1 2 3 4 Abdel-Wahab M, et al. (Feb 2015). "Update on transcatheter aortic valve replacement". Trends Cardiovasc Med. 25 (2): 154–161. doi:10.1016/j.tcm.2014.10.001. PMID 25453986.
  10. ↑ Steinberger, JD; McWilliams JP; Moriarty JM (10 April 2015). "Alternative Aortic Access: Translumbar, Transapical, Subclavian, Conduit, and Transvenous Access to the Aorta.". Tech Vasc Interv Radiol 18 (2): 93–99. doi:10.1053/j.tvir.2015.04.007. PMID 26070621.
  11. ↑ Greenbaum, AB; ONeill WW; Paone G; Guerrero M; Wyman JF; Cooper RL; Lederman RJ (1 July 2014). "Caval-aortic access to allow transcatheter aortic valve replacement in otherwise ineligible patients. Initial human experience.". J Am Coll Cardiol 63 (25 Pt A): 2795–2804. doi:10.1016/j.jacc.2014.04.015. PMID 24814495.

Further reading


This article is issued from Wikipedia - version of the Friday, January 22, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.